MedPath

Ga-68 FAPI PET Before Immunotherapy

Not Applicable
Recruiting
Conditions
Mesotheliomas Pleural
Registration Number
NCT06451536
Lead Sponsor
Ankara University
Brief Summary

It is aimed to evaluate FAP expression and its success in predicting treatment response before immunotherapy used in the treatment of malignant mesothelioma with Ga68 FAPI PET/CT imaging, which allows in vivo evaluation of FAP expression, which is thought to be associated with immunosuppression and resistance to immunotherapy.

Detailed Description

Patients diagnosed with pleural mesothelioma and planned for immunotherapy will be included in the study. Patients will undergo Ga68 FAPI PET/CT imaging within 10 days before the start of immunotherapy treatment, and SUVmax, SUVmean, metabolic tumor volume and total Ga68 FAPI uptake parameters will be obtained from the tumors. Following this, the routine treatment and follow-up of the patients will be carried out by their clinicians. It will be evaluated whether there is a correlation between treatment response and initial Ga-68 FAPI PET findings.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Having a histopathologically confirmed diagnosis of
  • Pleural Mesolthelioma
  • Patients scheduled for immunotherapy with anti-PDL-1 and/or anti-CTLA-4 antibodies as first or second line therapy
  • Patients who gave informed consent form to participate in the study
Exclusion Criteria
  • ECOG>2
  • Patients who did not provide informed consent form to participate in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Prediction of immune therapy response with Ga-68 FAPI PET6. month after initiation of therapy

prediction of immunotherapy response with total lesion FAPI uptake measured with Ga-68 FAPI PET before immunotherapy

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Ankara University School of Medicine

🇹🇷

Ankara, Turkey

Ankara University School of Medicine
🇹🇷Ankara, Turkey
Cigdem Soydal, Asc Prof
Contact
+903125957632
csoydal@ankara.edu.tr

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.